Solid organic growth and record Q3 margins were achieved, with all business areas contributing and strong cash flow supporting continued M&A and share buybacks. Outlook remains positive but cautious due to geopolitical risks and expected normalization of Medical Solutions sales.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.